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ABSTRACT
Gastric cancer is one of the most common upper gastrointestinal malignancies. To date, enteral immunonutrition (EIN) 
has gained increasing attention as it is found to effectively enhance the host’s immunity and improve the metabolic 
status of gastric cancer patients undergoing gastrectomy. The health-boosting effects of EIN are believed to originate 
from a number of nutritional elements such as omega-3 fatty acids, glutamine, arginine and nucleic acid precursors that 
help reduce the incidences of post-operative complications and shorten the length of hospital stay among the 
aforementioned patients. However, little was known about the consistency of health-boosting benefits conferred by EIN. 
Hence, according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) protocol, this 
systematic review was carried out using nine meticulously and specifically selected full-length articles focusing on the 
pre- and post-operative effects of EIN including physical, biochemical, clinical and immunological outcomes on gastric 
cancer patients. Among the selected articles, seven of them focused on post-operative EIN while the remaining two 
concentrated on pre-operative EIN. In most of the selected studies, more than one immunonutritional components 
(arginine, glutamine, omega-3 fatty acid, RNA) were integrated. Patients receiving EIN showed significantly improved 
immunity, for example, increase in CD4+ T and NK cell counts that are responsible for fighting pathogens. In addition 
to that, individuals receiving EIN also showed increased levels of inflammatory biomarkers in their sera such as pre-
albumin and transferrin. This results in shorter period of post-operative hospital stay that in turn permits progressive 
healing process and increases the survival rate due to minimal frequency of post-operative infections. Conclusively, our 
systematic review acknowledges that regardless of the initiation timing (pre-operative or post-operative) of 
immunonutrition, EIN can improve the overall health status of gastric cancer patients including infection complications 
and the length of hospital stay through regulation of immune responses.
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ABSTRAK
Kanser gastrik adalah salah satu kanser yang umum di bahagian atas gastroperut. Kini, imunonutrisi enteral (EIN) 
semakin mendapat perhatian kerana pendekatan ini didapati dapat meningkatkan keimunan tubuh badan dan 
memperkukuh fungsi metabolik badan bagi pesakit yang menjalani gastrektomi. Kesan peningkatan kesihatan EIN 
dipercayai berasal daripada unsur pemakanan seperti asid lemak omega-3, glutamin, arginin dan prekursor asid 
nukleik yang dapat mengurangkan kejadian komplikasi pasca-operasi dan memendekkan tempoh penginapan di 
hospital dalam kalangan pesakit tersebut. Namun, konsistensi manfaat EIN dalam meningkatkan kesihatan masih 
kurang perinci. Oleh itu, dengan berpandukan protokol PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses), kajian tinjauan sistematik ini telah dijalankan dengan teliti dengan menggunakan sembilan artikel 
penuh spesifik yang memfokuskan kesan pra- dan pasca-operasi EIN yang merangkumi segi fizikal, biokimia, klinikal 
dan keimunan dalam kalangan pesakit kanser gastrik. Antara artikel yang terpilih, tujuh daripadanya tertumpu pada 
kesan pasca-operasi EIN manakala dua artikel lagi menumpu pada kesan pra-operasi EIN. Kebanyakan kajian terpilih 
menggabungkan lebih daripada sejenis komponen imunonutrisi (arginina, glutamina, asid lemak omega-3, RNA). 
Pesakit yang menerima EIN menunjukkan peningkatan dalam penanda biologi seperti bilangan sel T CD4+ dan NK 
yang bertanggungjawab untuk melawan patogen. Tambahan pula, individu yang menerima EIN juga menunjukkan 
peningkatan dalam aras serum penanda inflamasi seperti pra-albumin and transferrin. Hal ini memendekkan tempoh 
penginapan pasca-operasi di hospital, seterusnya mempercepat proses penyembuhan dan meningkatkan kadar 
kemadirian akibat penurunan kebarangkalian jangkitan pasca-operasi. Secara konklusi, ulasan sistematik ini mendapati 
tanpa kira masa permulaan imunonutrisi (pra-operasi atau pasca-operasi), EIN dapat menambah baik status kesihatan 
pasakit kanser gastrik secara keseluruhan termasuk komplikasi jangkitan dan tempoh penginapan hospital melalui 
regulasi tindak balas keimunan. 
Kata kunci: Arginina; asid lemak omega-3; glutamina; imunonutrisi enteral; kanser gastrik; RNA
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INTRODUCTION
Cancer is a collective term for a large group of diseases 
characterized by the growth of anomalous cells beyond 
their usual perimeter that allows them to invade adjoining 
parts of the body and/or advance to the other organs. Cancer 
is known to be the second leading cause of death globally 
and is estimated to account for 9.6 million deaths in 2018 
(WHO 2018). Cancers that are most commonly identified 
in male are lung, prostate, colorectal, stomach and liver 
cancers whilst breast, colorectal, lung, cervix, and thyroid 
cancers are the most common among women (Choo et al. 
2019; Md Pauzi et al. 2019; Nies et al. 2018; Yap et al. 
2018, 2017).
Cancer incidences are hiking up in Malaysia. In 2014, 
cancers contributed 13.02 % of all deaths in the Ministry 
of Health (MOH) hospitals compared to 9.23 % in 1994 
(Ministry of Health Malaysia 2017). Among the cancer 
incidences, gastric cancer was the eighth most common 
cancer in male and tenth in female with the highest 
incidence rate recorded among Chinese followed by Indian 
and Malay for both sexes (Azizah et al. 2016).
Patients with gastrointestinal (GI) tract neoplasms 
usually suffer from malnutrition (Choi & Kim 2016; Liu 
et al. 2017) and suppressed immune functions (Schattner 
2003). This situation might be worsened by major elective 
surgery. Hence, provision of adequate nutrition becomes 
an important approach in managing patients with gastric 
cancer. 
Total parenteral nutritional (TPN) and enteral 
nutritional (EN) supports are sought after in clinical 
settings to help immune-suppressed gastric cancer patients. 
The EN is emphasized for patients with GI malignancy 
during the perioperative period to accelerate bowel 
function recovery and improve nitrogen balance and 
immune response while reducing post-operative 
complications and hospitalization time (Liu et al. 2012). 
In addition to conventional enteral nutrition, application 
of immunonutrition (IN) containing arginine, glutamine, 
omega-3 fatty acids and nucleotides (RNA), either alone 
or in combination, has gained increasing attention due to 
various improved health benefits seen among patients 
following enteral immunonutritional (EIN) support 
(Fujitani et al. 2012). 
Surgery is the key curative treatment for gastric cancer. 
However, the total gastrectomy is known to be associated 
with post-operative catabolism, and perturbation in 
metabolic, endocrinal, neuroendocrinal and immune 
systems which in turn contribute to high post-operative 
morbidity among gastric cancer patients (Fujitani et al. 
2012). On that account, IN is a promising treatment option 
for them in order to modify their metabolic status and 
immune responses, reduce the incidence of post-operative 
complications and shorten the length of hospital stay. This 
systematic review on the outcomes of IN among gastric 
cancer patients receiving enteral IN (EIN) in the pre-and 
post-operative periods intends to provide reliable empirical 
evidence to corroborate the aforementioned health-
improving benefits of IN. In this systematic review, the 
effectiveness of EIN in gastric cancer patients was 
deliberately reviewed in terms of pre- and post-operative 
outcomes. The positive outcomes of EIN such as improving 
the patients’ overall health status, reducing post-operative 
infection complications and the period of hospitalization 
are greatly attributed to the immune-boosting elements in 
the EIN.
METHODS
PROTOCOLS AND REGISTRATION
The protocol and guidelines for preparing this systematic 
review were based on the PRISMA (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses) 
statement.
ELIGIBILITY CRITERIA AND SELECTION CRITERIA
In the primary screening, all duplicate articles were 
removed and publications deviating from this review goal 
were excluded. Reports that described gastric cancer 
patients receiving pre- or post-operative EIN were 
included. Reports involving interventional approaches 
were selected over observational or case-control studies. 
The selected reports were assessed for the quality and 
equality of methodology. Finally, according to the 
objectives and eligibility criteria of this review, we 
included studies that: described interventions in the form 
of clinical trials with randomized controlled (blind or non-
blind experiment, open-label) and/or non-randomized and/
or non-controlled trials; involved adult (>18 years) gastric 
cancer patients; implicated male and/or female (non-
pregnant/lactating) gastric cancer patients; described pre- 
and post-operative EIN interventions via oral or enteral 
feeding tubes; described interventions with or without 
control groups, and control groups with or without placebo 
or any other interventions. The exclusion criteria were: 
studies without interventions and non-clinical studies; 
non-reviewed articles; patients having the other combined 
cancers; patients on the parenteral nutrition; patients 
receiving immunosuppressive drugs, and patients 
undergoing radiotherapy.
Studies were identified and selected through electronic 
search and article screening from databases such as 
PubMed (1968 to October 2018), OVID (1980 to October 
2018), EBSCOhost (1980 to October 2018) and 
COCHRANE. According to PICOs, the keywords and text 
terms used in COCHRANE comprising gastric cancer 
patients (population), clinical trial (study design), pre- and 
post-operative EIN (intervention), laboratory indices and 
clinical outcomes (outcome) were used. Laboratory indices 
included interleukin-2 (IL-2), immunoglobulin-G (IgG), 
serum albumin whereas clinical outcomes included the 
length of hospital stay and post-operative complications. 
In PubMed, OVID and EBSCOhost, medical subject 
headings (MeSH) defining the PICOs such as ‘Gastric 
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Neoplasm’, ‘Gastric Cancer’, ‘Gastric Tumor’, ‘Gastric 
Carcinoma’, ‘Arginine’, ‘Glutamine’, ‘ω-3 Fatty Acids’, 
‘Enteral Immune Nutrition’, ‘Immune-Enhancing Enteral 
Nutrition’, ‘Immunoenhanced Enteral Nutrition’ and 
‘Enteral Immunonutrition’ were used to select eligible 
reports. All studies were limited to full-text articles 
describing human studies published in the English 
language. Conference abstracts and proceedings were 
excluded.
INFORMATION SOURCES AND SEARCH STRATEGY
Keywords used for literature search included gastric 
cancer; gastrectomy, enteral immunonutrition; omega-3 
fatty acids; glutamine; arginine; ribonucleic acid (RNA), 
pre-operative, post-operative. Table 1 summarizes time-
frame and chronology of literature search and MeSH used 
for literature search.
DATA COLLECTION AND STUDY CHARACTERISTICS
In this systematic review, characteristics of each selected 
study were extracted, analysed and cited. Data were pulled 
out and categorized according to five ‘PICOS’ components 
in order to maintain the explicitness of this review: patient 
population (P); interventions or exposure of interest (I); 
comparators (comparison between interventions) (C); main 
outcomes or endpoint of interest (O); and the chosen study 
design (S). The data were further refined to the following 
characteristics: study (setting, type of study design, 
eligibility criteria), patient population (number of 
participants, age, gender, ethics) and control groups, EIN 
(duration, dosage/prescription/contents) and control 
regimen. Post-operative adverse effects observed in 
intervention groups receiving EIN were also extracted.
DATA ANALYSIS AND SUMMARY MEASURES
Measurable outcomes especially laboratory indices were 
recorded in respective units. The following laboratory 
indices of the selected studies were compared:
C-reactive protein (CRP) (mg/dl); Serum albumin (g/L); 
IL-2 and tumour necrosis factor alpha (TNF-α) (pg/mL); 
Immunoglobulin-M (IgM) and IgG (g/L); and CD4+ and CD8+ 
T cells (%).
The eligibility and validity of the selected articles (risk 
of bias) were analysed using the Cochrane Collaboration’s 
tool adapted from Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 (Table 2) (Cochrane 
Back & Neck 2011; Higgin et al. 2011). This is to minimize 
bias during data extraction from the selected articles.
RESULTS
STUDY CHARACTERISTICS
In this systematic review, 75 studies were initially 
identified across four electronic databases. After removal 
of 8 duplicates and 34 irrelevant studies, 33 articles were 
eligible for further full-text screening of which 24 articles 
did not meet the criteria of article selection. Thus, only 9 
articles with a total number of 780 subjects were included 
in the final analysis. The flow of article selection and 
screening was outlined in Figure 1.
The eligibility of the selected articles was assessed 
using the Cochrane Collaboration’s tool. Due to lack of 
data, the risk of bias for a few factors could not be 
completely determined, such as the allocation concealment, 
blinding of the participants and personnel, blinding of 
outcome assessors and funding (Table 2). However, two 
major contributing components of this systematic review 
were free from risk of bias: outcome data and reporting. 
This permitted us to proceed with the systematic review 
of the selected articles.
The characteristics and selection parameters of the 
selected articles were tabulated in Table 3. Most of the 
articles reported both laboratory findings and clinical and 
outcomes, and more than one immune-boosting element 
like arginine, glutamine, omega-3 fatty acid, RNA and 
others were incorporated in the IN. The EIN was supplied 
post-operatively in the majority of the studies whereas two 
studies supplied pre-operative EIN. Subjects in the studies 
were mostly elderly aged 60 years old and above, however, 
in a few studies, subjects aged 37 to 70 years old were 
involved. The studies were performed in China, USA, 
Japan, Spain and Italy.
IMPROVEMENT OF THE OVERALL HEALTH STATUS
Both pre- and post-operative EIN resulted in positive 
outcomes especially on the overall health status of the 
patients. In the majority of the studies, the incidences of 
post-operative infection complications in the immune-
enhancing diet (ID) group were significantly (p<0.05) 
lower (0 - 7.4 %) than that of the conventional diet (CD) 
group (9.3 - 28 %). This is in line with the significantly 
lower number of post-operative infections in the ID group 
(2 cases) than that of the CD group (8 cases) (p = 0.039). 
In addition to that, the anastomotic leak rate was also lower 
in the ID group (3.7 % vs 7.3 %, p<0.05) (Marano et al. 
2013; Okamoto et al. 2009; Scislo et al. 2018). The duration 
of Systemic Inflammatory Response Syndrome (SIRS) 
was therefore significantly (p<0.05) shorter (0.77±0.9 
days) in the ID group than that observed in the CD group 
(1.34 ± 1.45 days) (Okamoto et al. 2009). These findings 
prove that EIN supplemented with arginine, omega-3 fatty 
acids and RNA in the early post-operative period 
strengthens the immunity of gastric cancer patients 
undergoing gastrectomy. They showed increased collagen 
synthesis and demonstrated improved surgical wound 
healing which in turn reduced general morbidity (Farreras 
et al. 2005) omega-3 fatty acids and ribonucleic acid (RNA. 
A significant reduction of CD4+ T cell count was observed 
in several reports (Braga et al. 1999; Marano et al. 2013; 
Okamoto et al. 2009). The CD4+ T cell count of the ID 
group on day-7 post-operation was significantly lower than 
that of the standard enteral nutrition group (352 ± 45 vs 
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TABLE 1. Database search details and MeSH used for literature search
No. Item Explanation
1. Date of literature search 24 September 2018 - 21 December 2018.
2. Period cover by the literature search Multiple databases were systematically searched and the review included all 
publications in the past 15 years (December 2003 - December 2018).
3. Literature sources used to identify 
data 
There are various sources of literature used which include the following sources: 
1. Electronic literature search 
2. Scientific databases
3. Citations referenced in scientific literature 
A comprehensive search strategy was used to identify and access the relevant 
literature, involving multiple databases like PubMed, OVID, EBSCOhost and 
Cochrane library.
The search strategy for selection of literature was documented and justified where 
objective, non-biased and systematic search and review methods were employed. 
The uses of precise search term were applied to reduce the risk of missing studies.
The title, abstract and full text studies were assessed according to eligibility criteria. 
Then, the data were extracted using a standardized form and being summarized in a 
descriptive table.
4. Databases search details Databases were searched using the following keywords for title and abstract: 
1. Clinical trial AND gastric cancer OR gastrectomy
2. Gastric cancer AND pre-operative AND post-operative 
3. Gastric cancer AND post-operative 
4. Gastric cancer AND pre-operative AND post-operative 
5. Enteral immunonutrition and gastric cancer 
6. Pre-operative enteral immunonutrition AND post-operative enteral 
immunonutrition
7. EffectivenessOR efficacy of enteral immunonutrition AND gastric cancer 
Our search strategy identified 75 potential studies through electronic search. Most 
of the studies (N=66) were excluded following the database search details and 
exclusion criteria. The remaining studies (N=9) met the eligibility criteria and 
included in the review.
5. Selection criteria used to choose 
articles 
Inclusion criteria
1. Male or female adult gastric cancer patients aged >18 years 
2. Described pre- and post-operative EIN interventions via oral or enteral feeding 
tubes
3. Described interventions with or without control groups
4. Control groups with or without placebo or any other interventions. 
5. Interventions in the form of clinical trials with randomized controlled (blind 
or non-blind experiment, open  label) and/or non-randomized and/or non-
controlled trials
Exclusion criteria 
1. The studies without interventions and non-clinical studies
2. Non-reviewed articles
3. Patients having other combined cancers
4. Patients on parenteral nutrition
5. Patients receiving immunosuppressive drugs
6. Patients on radiotherapy
542 ± 53, p=0.032). Such reduction implies EIN is capable 
of limiting CD4+ T cell-mediated pro-inflammatory 
responses that are commonly associated with post-
operative complications. Furthermore, those receiving EIN 
also showed improved serum levels of total serum protein, 
albumin, pro-albumin, transferrin, NK cells, IgM, IgG, 
inflammatory cytokines such as IL-6 and TNF-α (Chen et 
al. 2015; Farreras et al. 2005; Liu et al. 2012; Scisslo et al. 
2018; Marano et al. 2013; Zhao et al. 2013). The improved 
levels of serum proteins might indicate better nutritional 
status of the individuals whereas the increased levels NK 
cells, antibodies and cytokines could mean better cell-
mediated and humoral responses that protect them from 
post-operative infections and complications.  
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Despite the benefits of EIN as discussed in the majority 
of the articles, two studies showed no significant differences 
in the post-operative pulmonary infections between the 
immunonutrition group and the control group (Liu et al. 
2012; Zhao et al. 2013). Fujitani et al. (2012) also showed 
that the five-day pre-operative EIN failed to prevent early 
clinical outcomes of systemic acute-phase responses in 
well-nourished gastric cancer patients undergoing elective 
total gastrectomy. 
OVERALL LENGTH OF HOSPITAL STAY
Generally, the length of hospital stay is used to indicate 
the efficiency of a treatment. Among the nine chosen 
randomized controlled trials, four of the studies found the 
length of hospital stay of those receiving IN was 
significantly shorter (12.7 ± 2.3 - 23.8 ± 16.6 days) 
compared to the control or standard diet group (15.9 ± 3.4 
- 25 ± 10.6 days) (Farreras et al. 2005; Liu et al. 2012; 
Marano et al. 2013; Okamoto et al. 2009). Zhao et al. 
(2013) however, reported no significant differences in the 
duration of hospital stay (P=0.73) between the arginine-
supplemented and control groups. The authors hypothesized 
that such variations could be affected by the relatively 
small sample size. 
Although post-operative EIN is generally beneficial 
to gastric cancer patients in the context of improving their 
overall health and reducing the length of hospital stay, 
certain individuals may not experience the advantages, as 
do the other patients. This is largely due to some inherent 
biological factors such as the body metabolism and serum 
protein levels, and the individual immunity. 
DISCUSSION
Generally, IN is defined as utilization of specific nutritional 
elements to modulate the immune system, which in turn 
improves certain injury or disease states (Chow & Barbul 
2014). In IN, supranormal quantities of nutrients are 
supplied via the enteral or parenteral route to achieve 
pharmacological effects (Grimble 2005). EIN refers to 
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FIGURE 1. The selection of eligible articles for analysis
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standard EN supplemented with specific immune-
promoting compounds, such as arginine, glutamine, 
omega-3 fatty acids and RNA. These compounds are 
responsible for strengthening immune defense and 
intestinal barriers, and modulating inflammatory responses 
(Chen et al. 2005). IN is recommended for patients 
undergoing abdominal surgery such as cancer and 
malnourished patients both pre-operatively and post-
operatively.
The experimental and clinical findings have proven 
the benefits of IN particularly in up-regulating the host’s 
immunity, controlling inflammatory responses, modulating 
the synthesis of acute-phase and constitutive proteins, 
improving gut oxygenation and barrier functions after 
injury, and reducing morbidity and mortality due to post-
operative infections (Gianotti et al. 2002). This is especially 
evident in gastric cancer patients undergoing surgery. Their 
nutritional status deteriorates after gastrectomy. This often 
leads to decreased food intake and reduced body weight 
(Shim et al. 2013). As a result, malnutrition in this 
population causes them more susceptible to infection 
complications. In addition to that, IN also ensures well-
regulated inflammatory responses take place after surgery. 
Controlled inflammatory responses are essential for 
wound healing, immune processes and successful 
recovery from an earlier surgery. This is because any 
uncontrollable systemic inflammatory events may lead 
to organ dysfunction and adverse outcomes (Chen et al. 
2005).
The nutritional constituents included in an IN formula 
play an important role in balancing the inflammatory and 
anti-inflammatory responses. The functions of a few 
commonly employed immune-boosting nutrients, such as 
omega-3 fatty acids and amino acids are described as 
follows:
OMEGA-3 FATTY ACIDS
Omega-3 fatty acids (FAs) generally modulate the 
structural and functional integrity of cell membranes, 
intercellular signal transduction and synthesis of 
eicosanoids (important immune mediators) (Alexander 
1998; Chan et al. 2005). Fish oil-derived omega-3 fatty 
acids displace arachidonic acid (AA) of immune cell 
membranes, thus reduces the production of inflammatory 
prostaglandins and prostacyclins (Martin & Stapleton 
2010), as well as cytotoxicity of inflammatory cells (Hegazi 
et al. 2014). Fish oil-derived omega-3 FAs such as 
eicosapentaenoic and docosahexaenoic acids are also 
precursors of resolvins. They help reduce cellular 
inflammation through inhibition of inflammatory cell 
migration and mediators to affected sites (Hegazi et al. 
2014). 
ARGININE
Arginine stimulates secretion of a variety of hormones, 
such as growth hormones, glucagons and insulin that exert 
concerted modulatory effects on immune responses (Chen 
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TABLE 3. Characteristics of eligible studies
No. Authors & year 
of publication
Country Diagnosis Ages of 
patients (years)
Sample size 
(EIN/EN)
Elements of 
EIN
Nature of EIN Duration of EIN 
support (days)
Mode of 
enteral feeding
Outcomes (Improvement)
Pre-operative administration
1. Okamoto et al. 
(2009)
Japan Gastric 
adenocarcinoma
66.9±11.5 (EIN) 
70.9±13.2 (EN)
30/30 Arginine, 
omega-3 fatty 
acids & RNA
Standard EN 7 Oral CD4+, CD8+, SIRS, lymphocytes, LHS, 
post-operative complications, operation 
time, intra-operative blood loss.
2. Fujitani et al. 
(2012)
Japan Gastric 
adenocarcinoma
64 (26-78) EIN
65 (30-79) (EN)
120/111 Arginine & 
RNA
Regular diet 5 Oral Mortality, pulmonary infections, post-
operative complications.
Post-operative administration
1. Liu et al. 
(2012)
China Advanced 
gastric cancer
57.3±7.1 (EIN)
58.4±6.3 (EN)
56.2 ± 6.7
(Control)
28/24/26 Arginine & 
glutamine
Standard EN 7 Nasoenteral Total protein, albumin, proalbumin, 
transferrin, CD4+, CD8+, IgM, IgG, 
LHS, post-operative complications, 
incision infections, pulmonary infection.
2. Chen et al. 
(2005)
China Gastric 
carcinoma
NA 20/20 Arginine, 
glutamine & 
omega-3 fatty 
acids
Standard EN 7 Nasoenteral Proalbumin, albumin, transferrin, CD4+, 
CD8+, IgM, IgG.
3 Mochiki et al. 
(2011)
Japan Gastric cancer 65±2.6 (EIN)
59±2.1 (EN)
15/16 Glutamine Oral 
placebo
NA Oral Operation time, intra-operative blood 
loss.
4 Farreras et al. 
(2005)
Spain Gastric cancer 66.7±8.3(EIN)
69.2±13.8 (EN)
30/30 Arginine, 
glutamine 
&omega-3 
fatty acids
Standard EN 7 Oral Total protein, albumin, proalbumin, 
lymphocytes, incision infections, 
pulmonary infections, post-operative 
complications, mortality.
5 Marano et al. 
(2013)
Italy Gatric 
adenocarcinoma
66.6 (55-78) 
(EIN)
65.1 (49-83) 
(EN)
54/55 Arginine, 
glutamine, 
omega-3 fatty 
acids & RNA
Standard EN 7 Oral Total protein, albumin, transferrin, 
CD4+, CD8+, lymphocyte, LHS, SIRS, 
incision infections, post-operative 
complications, operation time, mortality, 
intra-operative blood loss.
6 Scisslo et al. 
(2018)
USA Gastric Cancer 62.6 (EIN)
62.9 (Control)
44/54 Arginine, 
omega-3 fatty 
acids & RNA
Protein-rich, 
isocaloric, no-
residue diet
6 Naso-jejunal 
feeding
Infections, wound healing and 
pneumonia.
7 Zhao et al. 
(2013)
China Gastric cancer 37 - 59 (EIN)
36 -56 (EN
37/36 Arginine Standard EN 7 Tube feeding Incision and pulmonary infections.
LHS: Length of hospital stay; SIRS: systemic inflammatory Response Syndrome
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et al. 2005). Therefore, arginine is a crucial immune-
modulating nutrient and also a precursor for nitric oxide 
(NO) synthesis (Hegazi et al. 2014). Clinical studies 
evaluating the effects of enteral arginine supply 
demonstrated net nitrogen retention, increased protein 
synthesis and improved wound healing (Barbul 1986). 
Arginine, therefore, helps improve systemic inflammatory 
responses resulted from unbalanced release of NO. An 
immune-modulating enteral diet containing increased 
amounts of arginine and fish oil is therefore, advocated in 
all high-risk patients undergoing major surgery (Hegazi et 
al. 2014).
GLUTAMINE
Glutamine is the most abundant amino acid in the plasma 
and a primary metabolic fuel for rapidly proliferating cells 
(Chow & Barbul 2014). It helps maintain gut barrier 
functions, induces expression of heat shock proteins and 
stimulates nucleotide synthesis (Wischmeyer 2007). 
During catabolic stress due to trauma, sepsis and burn, 
glutamine is rapidly released from muscle stores and 
serum; this, in turn, reduces the expression of inflammatory 
cytokines. As a result, the induction of heat shock protein 
synthesis via glutamine supplementation may promote 
inflammatory responses that are needed to fight post-
operative infections, hence shorter hospital stay and 
ventilator time among critically ill patients (Singleton et 
al. 2005). Therefore, glutamine becomes conditionally 
essential to patients undergoing physiological stress 
conditions (Lacey & Wilmore 1990).
LIMITATIONS
We acknowledge a number of limitations of this systematic 
review. The non-English studies were not included in this 
review. Due to the lack of relevant articles, local studies 
were also excluded. The EIN-related indicators such as 
cost-effectiveness were not reported due to inconsistent 
data presentation in the selected articles. Considerable 
between-study heterogeneity on the biochemical and 
clinical outcomes was observed. Besides, we also faced 
difficulties to match the outcomes due to geographical 
differences. Regardless of the limitations, we still carried 
out the assessment of Risk of Bias using the Cochrane 
Collaboration’s tool in order to ensure an objective data 
analysis.
CONCLUSION
Regardless of the initiation timing (pre-operative and post-
operative) of IN, this systematic review clearly demonstrates 
that IN comprising various immune-boosting elements is 
able to improve overall health status of gastric cancer 
patients especially infection complications and the length 
of hospital stay through modulation of immune responses. 
In order to ensure a more consistent reporting of the robust 
health benefits of IN, more randomized control trials with 
a better quality of methods and a larger sample size are 
warranted. In the nutshell, pre- and post-operative IN 
supplementation is recommended for gastric cancer 
patients. An effective immune-modulating diet is suggested 
to begin at least 5 days prior to a surgery and be continued 
through the post-operative period whenever such initiation 
is feasible (Marik & Zaloga 2010). This is believed to 
provide additional energy and nitrogen supplies for wound 
healing and to compensate impaired immune responses 
resulted by the earlier surgery (Gianotti et al. 2002).
There are several practical recommendations made 
based on McCowen and Bistrian (2003) to maximize the 
success of EIN such as: arginine should be >12 g/L; 
duration of EIN should be >3 days, preferably 5-10 days; 
nasogastric feeding should be executed every 4-6 h, and 
gastric residuals of ≈ 200 mL should be acceptable; and 
feeding goal should reach 25 kcal/kg, and ≥ 800 mL/d 
should be given for optimum outcomes.
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